 |
PDBsum entry 4csv
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Science
347:882-886
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism.
|
|
C.Wilson,
R.V.Agafonov,
M.Hoemberger,
S.Kutter,
A.Zorba,
J.Halpin,
V.Buosi,
R.Otten,
D.Waterman,
D.L.Theobald,
D.Kern.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Macromolecular function is rooted in energy landscapes, where sequence
determines not a single structure but an ensemble of conformations. Hence,
evolution modifies a protein's function by altering its energy landscape. Here,
we recreate the evolutionary pathway between two modern human oncogenes, Src and
Abl, by reconstructing their common ancestors. Our evolutionary reconstruction
combined with x-ray structures of the common ancestor and pre-steady-state
kinetics reveals a detailed atomistic mechanism for selectivity of the
successful cancer drug Gleevec. Gleevec affinity is gained during the
evolutionary trajectory toward Abl and lost toward Src, primarily by shifting an
induced-fit equilibrium that is also disrupted in the clinical T315I resistance
mutation. This work reveals the mechanism of Gleevec specificity while offering
insights into how energy landscapes evolve.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |